Search Results - "Manzyuk, Lyudmila"

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation by Miles, David, Cameron, David, Bondarenko, Igor, Manzyuk, Lyudmila, Alcedo, Juan Carlos, Lopez, Roberto Ivan, Im, Seock-Ah, Canon, Jean-Luc, Shparyk, Yaroslav, Yardley, Denise A, Masuda, Norikazu, Ro, Jungsil, Denduluri, Neelima, Hubeaux, Stanislas, Quah, Cheng, Bais, Carlos, O'Shaughnessy, Joyce

“…Abstract Aim MERiDiAN evaluated plasma vascular endothelial growth factor-A (pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in…”
Get full text

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer by McMeekin, Scott, Dizon, Don, Barter, James, Scambia, Giovanni, Manzyuk, Lyudmila, Lisyanskaya, Alla, Oaknin, Ana, Ringuette, Sarah, Mukhopadhyay, Pralay, Rosenberg, Julie, Vergote, Ignace

“…Abstract Objective The purpose of this multicenter, open label, randomized phase III study was to determine whether ixabepilone resulted in improved overall…”
Get full text

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial by Heigener, David F., Pereira, José Rodrigues, Felip, Enriqueta, Mazal, Juraj, Manzyuk, Lyudmila, Tan, Eng Huat, Merimsky, Ofer, Sarholz, Barbara, Esser, Regina, Gatzemeier, Ulrich

“…The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly…”
Get full text

Bevatsizumab v kombinatsii s khimioterapiey pri rake molochnoy zhelezy by Lyudmila Valentinovna Manzyuk, Elena Igorevna Kovalenko, Elena Vladimirovna Artamonova, Lyudmila Ivanovna Osmanova

Get full text